This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035.
- In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035.
- There will be an increase in therapies with longer duration of action, such as Novo's CagriSema (semaglutide + cagrilintide) and zenagamtide, Eli Lilly's tirzepatide and retatrutide, and Amgen's MariTide, consequently improving patient compliance for obesity patients who may already experience a heavy treatment burden due to comorbid conditions.
- Multi-organ label expansion is broadening the clinical and reimbursement rationale, with glucagon-like peptide 1 (GLP-1) agents moving beyond weight loss and type 2 diabetes (T2D) and into cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), and chronic kidney disease (CKD), among other indications.
- Therapies with new routes of administration will enter the market, such as Novo's Wegovy pill (oral semaglutide), Eli Lilly's Foundayo (orforglipron), Structure Therapeutics' GSBR-1290, and other oral agents with different mechanisms of actions, such as enobosarm.
Scope
- Overview of obesity, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized obesity therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2025 and forecast for 10 years to 2035.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the obesity therapeutics market.
- Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for obesity treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 7MM obesity therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.